GP2 + GM-CSF has been assessed in the adjuvant setting in a phase IIB placebo-controlled randomized clinical trial including node-positive and high-risk node-negative HER2+ (any grade of IHC expression) BC patients after standard treatment completion. The gene discussed is ERBB2; the disease is breast cancer.